A Prospective Phase II Clinical Trial Evaluating the Efficacy and Safety of Adebrelimab in Combination With Trastuzumab Rezetecan for Patients With Stage III Unresectable HER2-Positive NSCLC
Clinical trial NCT07778745 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07778745
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-08-20
- Primary completion
- 2027-08-30
- Enrollment
- 37
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.